Association of Human Beta-Defensin 1 Gene Polymorphisms with Alopecia Areata Patients

January 2020 in “ Benha Journal of Applied Sciences ”

Adel A. Ibrahim, N.F. Alhusseiny, A.I. Mustafa, Atef Yousef

alopecia areata DEFB1 gene DEFB1 gene polymorphisms rs1800972 CG genotype GG genotype G allele AA beta-defensin 1

Studysummary This study found that DEFB1 polymorphisms, specifically the rs1800972 CG and GG genotypes, may predict susceptibility to and severity of alopecia areata. Our plain-language summary of this paper — not a Tressless recommendation.

This study investigated the association between DEFB1 gene polymorphisms and alopecia areata (AA) in 50 patients and 50 healthy controls. The results indicated that the DEFB1 rs1800972 genotypes (CG and GG) were significant predictors of more severe AA (p<0.001). The findings suggested that DEFB1 gene polymorphisms might influence the risk and severity of AA, with the CG, GG genotypes, and G allele being associated with increased susceptibility and severity of the condition.

View this study on bjas.journals.ekb.eg →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Oxidative Stress and Alopecia Areata

3 citations , June 2023 in “Frontiers in medicine”

This review discusses the association between oxidative stress and alopecia areata while proposing antioxidants as a potential supplementary therapy, but it reports no new clinical results.

research Hair Pull Test: Evidence-Based Update and Revision of Guidelines

36 citations , December 2016 in “Journal of The American Academy of Dermatology”

In this study, researchers evaluated the hair pull test and found that normal values should be reduced to two hairs or fewer, with no significant impact from hair washing, brushing, or lifestyle factors such as hair texture and medication use.

research The Autoimmune Basis of Alopecia Areata: A Comprehensive Review

162 citations , October 2014 in “Autoimmunity reviews”

This review discusses alopecia areata, highlighting its autoimmune aspects, environmental triggers, and current treatment options, but reports no new clinical results; recent studies suggest JAK pathway intervention may offer therapeutic potential.